美迪西：9月15日召开董事会会议

Group 1 - The core point of the article is that Medisi (SH 688202) announced a board meeting to discuss the first grant of restricted stock under the 2025 incentive plan, highlighting its focus on employee incentives and future growth strategies [1] - For the fiscal year 2024, Medisi's revenue composition shows that 99.96% comes from preclinical CRO (Contract Research Organization) business, indicating a strong reliance on this segment for income [1] - As of the report, Medisi's market capitalization stands at 10.9 billion yuan, reflecting its valuation in the market [1] Group 2 - The article mentions a significant breakthrough in a new drug recognized by both Chinese and American authorities for its breakthrough efficacy, which has generated excitement at the World Lung Cancer Conference [1]